Marché mondial des biosimilaires – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des biosimilaires

L'augmentation des compétences en recherche et développement a conduit à une augmentation de la disponibilité des biosimilaires. De plus, l'accent accru mis par la Food and Drug Administration sur l'amélioration de la pénétration des biosimilaires aide davantage le marché à étendre ses racines.

Français Data Bridge Market Research analyse que le marché mondial des biosimilaires, qui était de 37 270,20 millions USD en 2022, devrait atteindre 343 520,90 millions USD d'ici 2030 et devrait connaître un TCAC de 32,00 % au cours de la période de prévision 2023-2030. « Oncologie » domine le segment de produits du marché mondial des biosimilaires en raison de l'augmentation du nombre d'études de recherche, de l'augmentation des activités de recherche et développement des principaux acteurs axés sur l'oncologie et des avancées dans les technologies de la santé. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des biosimilaires

Market Definition

Biosimilar or follow-on-biologics that are almost an identical copy of an original product but however, is manufactured by another company. Biosimilar is used to treat a wide range of chronic and acute diseases and disorders. Biosimilar is are used to record electrical action produced by the human brain.

Biosimilar Market Dynamics

Drivers

• The Rise in the Prevalence of Diseases

 Surging prevalence of chronic and acute diseases all around the globe owing to various internal and external factors is one of the major factors responsible for fostering growth of the market. Rising patient pool especially in the developing economies coupled with growing cases of Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis is carving the way for the growth of the market.

• Research and Development Proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies have led to the advancements in the medical technology and have improved the quality of healthcare facilities.  Increasing number of screening tests for research proficiencies has further widened the scope of growth.

• Government Investments on Healthcare Infrastructure

The increase in the funding by the federal government is set to drive the growth of the market. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities. Also, growing acceptance of bioidentical hormones replacement therapy by the governmental healthcare facilities is also bolstering the market growth rate.

Opportunity

• Rising Demand for Biologic Drugs

The increasing prevalence of chronic diseases and the growing aging population have led to a rise in the demand for biologic drugs. Biosimilar can help meet this demand and improve patient access to these essential treatments.

Restraint/Challenge

• Regulatory Hurdles

Developing and gaining regulatory approval for biosimilar involves complex and stringent regulatory pathways. Manufacturers need to demonstrate similarity to the reference biologic through comprehensive analytical and clinical studies, which can be time-consuming and costly.

This global biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In July 2020, the FDA approved the adalimumab biosimilar, Hulio, developed by Fujifilm Kyowa Kirin Biologics, which is indicated for the subcutaneous treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis
•  In May 2020, Fresenius Kabi received the acceptance of the regulatory submissions for its proposed pegfilgrastim biosimilar (MSB11455) by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), respectively.

Global Biosimilar Market Scope

The global biosimilar market is segmented on the basis of product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Magnetic Resonance Imaging Scanners
• Computed Tomography Scanners
• Position Emission Tomography Scanners
• Biosimilar (EEG)
• Electromyography Devices (EMG)
• Magnetoencphalography Devices
• Transcranial Doppler Devices
• Intracranial Pressure Monitors (ICP)
• Electrodes
• Sensors
• Gels
• Cables

Drug Class

• Insulin
• Recombinant Human Growth Hormone (RHGH)
• Granulocyte Colony-Stimulating Factor
• Interferon
• Erythropoietin
• Etanercept
• Monoclonal Antibodies
• Follitropin
• Glucagon
• Calcitonin
• Teriparatide
• Enoxaparin Sodium

Type of Manufacturing

• In-House Manufacturing

• Contract Manufacturing

Procedure

• Invasive

• Non-Invasive

Disease

• Stroke

• Dementia

• Epilepsy

Indication

• Atrial Septal Defect (ASD)

• Ventricular Septal Defect (VSD)

• Patent Foramen Ovale (PFO)

• Aortic Valve Stenosis
• Others

Therapy Type

• Oncology

• Immunology
• Haematology
• Hormone Therapy
• Metabolic Disorders
• Others

End Users

• Hospitals

• Clinics
• Diagnostic Centres
• Others

Biosimilar Market Regional Analysis/Insights

The global biosimilar market is analysed and market size insights and trends are provided by country, product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users as referenced above.

The countries covered in the global biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the global biosimilar market because of the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending combined with the onset of COVID-19 pandemic and rising number of research activities in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, ever-rising geriatric population base and the growing demand for quality healthcare in the region.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global biosimilar market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for Biosimilar market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Biosimilar market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Biosimilar Market Share Analysis

The global biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global biosimilar market.

Some of the major players operating in the global biosimilar market are:

• Novartis AG (Switzerland)
•  Orion Pharma AB (Sweden)
•  Pfizer Inc. (U.S.)
• Samsung Bioepis. (South Korea)
•  Coherus BioSciences, Inc. (U.S.)
•  Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
•  Takeda Pharmaceutical Company Limited. (Japan)
•  Bristol-Myers Squibb Company (U.S.)
•  Merck KGaA (Germany)
•  Teva Pharmaceutical Industries Ltd. (U.S.)
•  Biocon. (India)
•  Bayer AG (Germany)
•  AbbVie Inc. (U.S.)
•  Allergan (Ireland)
•  Dr. Reddy’s Laboratories Ltd. (India)
•  Boehringer Ingelheim International GmbH. (Germany)
•  Biogen (U.S.)

SKU-12434